BARBARA L. HEMPSTEAD, MD, PHD
Osteopathic Medicine at 68 St, New York, NY
License number
New York 154920
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
525 E 68Th St, New York, NY 10021
Phone
(212) 746-2074
Personal information
See more information about BARBARA L. HEMPSTEAD at radaris.comName
Address
Phone
3180 44Th St APT 4B, Long Island City, NY 11103
60 Morning Glory Rd, Levittown, NY 11756
3180 44Th St, Astoria, NY 11103
60 Morning Glory Rd, Levittown, NY 11756
525 86Th St, New York, NY 10028
Professional information
Dr. Barbara L Hempstead, New York NY - MD (Doctor of Medicine)
Specialties:
Hematology, Medical Oncology, Oncology
Address:
New York Weil Cornell University ONC
525 E 68Th St, New York 10065
(212) 746-2060 (Phone)
525 E 68Th St, New York 10065
(212) 746-2060 (Phone)
Certifications:
Hematology, 1988, Internal Medicine, 1985, Medical Oncology, 1989
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
New York Weil Cornell University ONC
525 E 68Th St, New York 10065
NewYork-Presbyterian/Weill Cornell Medical Center
525 East 68Th St, New York 10065
525 E 68Th St, New York 10065
NewYork-Presbyterian/Weill Cornell Medical Center
525 East 68Th St, New York 10065
Education:
Medical School
Washington University St Louis
Graduated: 1982
New York Hospital
Graduated: 1983
Graduated: 1985
Washington University St Louis
Graduated: 1982
New York Hospital
Graduated: 1983
Graduated: 1985
Barbara Louise Hempstead, New York NY
Specialties:
Internal Medicine, Hematology, Medical Oncology, Hematology & Oncology
Work:
NewYork-Presbyterian / Weill Cornell
525 E 68Th St, New York, NY 10065
525 E 68Th St, New York, NY 10065
Education:
Washington University at St. Louis (1982)
High Affinity Ligand For P75 Neurotrophin Receptor
US Patent:
2003008, May 8, 2003
Filed:
May 24, 2002
Appl. No.:
10/155886
Inventors:
Barbara Hempstead - New York NY, US
Ramee Lee - New York NY, US
Kenneth Teng - New York NY, US
Pouneh Kermani - Great Neck NY, US
Ramee Lee - New York NY, US
Kenneth Teng - New York NY, US
Pouneh Kermani - Great Neck NY, US
International Classification:
A01N037/18, A61K038/00, C07K001/00, C07K014/00, C07K017/00
US Classification:
514/002000, 530/350000
Abstract:
The present invention provides an isolated protein comprising a pro-domain of a proneurotrophin, methods for producing the protein, and pharmaceutical compositions containing the isolated protein. The invention also provides a nucleic acid molecule which encodes the protein and a vector containing the nucleic acid molecule. The present invention further provides a method for cleaving a proneurotrophin protein to a mature neurotrophin. In addition, the invention relates to methods for inducing apoptosis in a cell of a mammal expressing p75 surface receptors or p75 and trk receptors. The methods include causing the p75 receptor to bind a pharmaceutical composition containing a pro-domain of a proneurotrophin or administering to the mammal an effective amount of a cleavage-resistant proneurotrophin and an inhibitor of trk activation. The invention also relates to a method for inhibiting apoptosis of a cell in a mammal by administering an effective amount of a molecule which inhibits binding of a proneurotrophin to a p75 receptor. Also provided, are kits and methods for screening a human for a condition associated with undesired apoptosis.
Methods For Regulating Angiogenesis And Vascular Integrity Using Trk Receptor Ligands
US Patent:
2010022, Sep 9, 2010
Filed:
May 21, 2010
Appl. No.:
12/785183
Inventors:
Barbara L. HEMPSTEAD - New York NY, US
Rosemary KRAEMER - Brooklyn NY, US
Shahin RAFII - Great Neck NY, US
Phi WIEGN - New York NY, US
Michael J. DONOVAN - Brookline MA, US
Rosemary KRAEMER - Brooklyn NY, US
Shahin RAFII - Great Neck NY, US
Phi WIEGN - New York NY, US
Michael J. DONOVAN - Brookline MA, US
Assignee:
CORNELL RESEARCH FOUNDATION, INC. - Ithaca NY
CHILDREN'S MEDICAL CENTER CORPORATION - Boston MA
CHILDREN'S MEDICAL CENTER CORPORATION - Boston MA
International Classification:
A61K 38/12, A61P 7/00
US Classification:
514 12
Abstract:
The present invention relates to methods of inducing or inhibiting the angiogenic process and promoting vessel growth or stabilization in an organ by modulating the trk receptor pathway. The present invention also relates to a method for treating a pathological disorder in a patient which includes administering a trk receptor ligand or an inhibitor or expression or activity of a trk receptor ligand. The present invention also relates to a method of screening for a modulator of angiogenesis, vessel growth, or vessel stabilization. Another aspect of the present invention is a method of diagnosing or monitoring a pathological disorder in a patient which includes determining the presence or amount of a trk receptor ligand or activation of a trk receptor ligand in a biological sample.
Method To Determine And Biomarker For Treatment Efficacy With Ssri, Snri, And Sari Antidepressants
US Patent:
2010024, Sep 23, 2010
Filed:
Jan 19, 2007
Appl. No.:
12/223053
Inventors:
Francis S. Lee - New York NY, US
Barbara L. Hempstead - New York NY, US
Kevin G. Bath - New York NY, US
Barbara L. Hempstead - New York NY, US
Kevin G. Bath - New York NY, US
International Classification:
C12Q 1/68, A61K 31/138, A61P 25/24
US Classification:
514651, 435 6
Abstract:
The invention provides a method for determining whether a patient suffering from a condition that is susceptible to treatment with a compound that activates the brain serotonin system is resistant to treatment with the compound. The method comprises observing whether the genome of the patient contains at least one copy of the BDNF allele containing a genetic alteration, and correlating the presence of the allele containing the genetic alteration with patients who are resistant to treatment with the compound. In another embodiment, the method comprises observing whether the patient expresses a BDNF protein containing an amino acid alteration, and correlating the expression of the BDNF protein containing the amino acid alteration with patients who are resistant to treatment with the compound.
Method For Determining Sensitivity Or Resistance To Compounds That Activate The Brain Serotonin System
US Patent:
2011020, Aug 25, 2011
Filed:
Jun 16, 2009
Appl. No.:
12/999581
Inventors:
Francis S. Lee - New York NY, US
Barbara Hempstead - New York NY, US
James Kocsis - Roxbury CT, US
Kevin Bath - New York NY, US
Barbara Hempstead - New York NY, US
James Kocsis - Roxbury CT, US
Kevin Bath - New York NY, US
Assignee:
CORNELL UNIVERSITY - Ithaca NY
International Classification:
A61K 31/135, C12Q 1/68, A61P 25/24
US Classification:
514651, 435 613, 435 611
Abstract:
The invention relates to a method for determining whether a patient suffering from a condition that is susceptible to treatment with a compound that activates the brain serotonin system is susceptible or resistant to treatment with the compound. The method includes establishing whether the patient is a pre-adult, a transition age patient, or an adult and observing whether the genome of the patient contains at least one copy of a BDNF allele having a genetic alteration. The method further includes correlating the presence of the allele containing the genetic alteration with susceptibility or resistance of the patient to the treatment with the compound, wherein a pre-adult patient containing the genetic alteration is correlated as being susceptible to the treatment; a transition age patient containing the genetic alteration is correlated as being susceptible or resistant to the treatment; and an adult patient containing the genetic alteration is correlated as being resistant to the treatment.
Methods For Increasing Capillary Density And Maintaining Viability Of Microvascular Cardiac Endothelial Cells Using Trk Receptor Ligands
US Patent:
7723293, May 25, 2010
Filed:
Oct 30, 2006
Appl. No.:
11/589659
Inventors:
Barbara L. Hempstead - New York NY, US
Rosemary Kraemer - Brooklyn NY, US
Shahin Rafii - Great Neck NY, US
Phi Wiegn - New York NY, US
Michael L. Donovan - Brookline MA, US
Rosemary Kraemer - Brooklyn NY, US
Shahin Rafii - Great Neck NY, US
Phi Wiegn - New York NY, US
Michael L. Donovan - Brookline MA, US
Assignee:
Cornell Research Foundation, Inc. - Ithaca NY
Children's Medical Center Corporation - Boston MA
Children's Medical Center Corporation - Boston MA
International Classification:
A61K 38/18
US Classification:
514 2, 514 12, 530399
Abstract:
The present invention relates to methods of inducing or inhibiting the angiogenic process and promoting vessel growth or stabilization in an organ by modulating the trk receptor pathway. The present invention also relates to a method for treating a pathological disorder in a patient which includes administering a trk receptor ligand or an inhibitor or expression or activity of a trk receptor ligand. The present invention also relates to a method of screening for a modulator of angiogenesis, vessel growth, or vessel stabilization. Another aspect of the present invention is a method of diagnosing or monitoring a pathological disorder in a patient which includes determining the presence or amount of a trk receptor ligand or activation of a trk receptor ligand in a biological sample.
Small Molecule Modulators Of Prongf Uptake
US Patent:
2011018, Aug 4, 2011
Filed:
Oct 8, 2009
Appl. No.:
13/122483
Inventors:
Barbara L. Hempstead - New York NY, US
Assignee:
CORNELL UNIVERSITY - Ithaca NY
International Classification:
A61K 33/00, A61K 31/12, A61K 31/198, A61K 31/366, A61P 25/28, A61P 25/24, A61P 25/14, A61P 9/00, A61P 9/10
US Classification:
424722, 514689, 514567, 514460
Abstract:
The present invention relates to a method of inhibiting cellular uptake of pro-nerve growth factor (proNGF) in a cell expressing neurotrophin p75 receptor in a mammal in need thereof. Such mammals include, for example, those suffering from neuropathological conditions. In another aspect, the invention relates to a method of promoting cellular uptake of proNGF in a cell expressing p75receptor in a mammal in need thereof. Such mammals include, for example, those suffering from conditions relating to human and other mammalian hair follicle cycling.
Methods Of Limiting Microvascular Damage Following Acute Myocardial Ischemia
US Patent:
2013011, May 9, 2013
Filed:
Jun 15, 2011
Appl. No.:
13/704404
Inventors:
Barbara Hempstead - New York NY, US
Chia-Jen Siao - New York NY, US
Chia-Jen Siao - New York NY, US
Assignee:
Cornell University - Ithaca NY
International Classification:
A61K 39/395, A61K 31/713
US Classification:
4241581, 514 44 A, 514 84, 4241721, 514 11
Abstract:
This disclosure has identified a new ligand-receptor system, proNGF and p75NTR/SorCS2, which is found to be involved in the microvascular functions of the heart. This disclosure provides methods for limiting microvascular damage following acute myocardial ischemia based on administration of an antagonist of this newly identified system, thereby promoting myocardial recovery.
Methods For Treating Early Stage Or Mild Neurological Disorders
US Patent:
2013033, Dec 19, 2013
Filed:
Nov 17, 2011
Appl. No.:
13/988193
Inventors:
Barbara L. Hempstead - New York NY, US
Taeho Kim - Palo Alto CA, US
Katrin Deinhardt - Southampton, GB
Moses Victor Chao - New York NY, US
Jianmin Yang - Forest Hills NY, US
Taeho Kim - Palo Alto CA, US
Katrin Deinhardt - Southampton, GB
Moses Victor Chao - New York NY, US
Jianmin Yang - Forest Hills NY, US
Assignee:
NEW YORK UNIVERSITY - New York NY
CORNELL UNIVERSITY - Ithaca NY
CORNELL UNIVERSITY - Ithaca NY
International Classification:
A61K 39/395, A61K 38/08, A61K 31/713, A61K 31/7088
US Classification:
4241581, 4241721, 514 44 R, 514 177, 514 44 A
Abstract:
This disclosure relates to modulation of the interactions between proNTs and p75/SorCS2 expressed on neuronal cells. Inhibition of such interactions is useful for reducing unwanted synaptic elimination, neurite pruning and/or other neuronal structural collapses, and for treating early stage and mild neurological disorders including mild cognitive impairment.